RecruitingPHASE1, PHASE2NCT05863234
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Studying Aggressive NK-cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hiroshima University Hospital
- Intervention
- PPMX-T003(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Hiroshima University Hospital, Hiroshima, Hiroshima, Japan
Collaborators
Kyoto University Hospital · Hokkaido University Hospital · Okayama University · Tokai University · Kyushu University · Tohoku University · Nagoya University · Komagome Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05863234 on ClinicalTrials.govOther trials for Aggressive NK-cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06716658JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT05941156Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell LeukemiaThe Affiliated Hospital of Xuzhou Medical University